Compare American Electric Power Company Inc (AEP) vs Summit Therapeutics Inc (SMMT) Price & Performance

American Electric Power (AEP) trades at $123.89, up 0.85% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 EPS versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, citing robust demand from data centers and a $78 billion capital plan. Valuation metrics include a P/E of 21.42 and P/B of 2.1, with a consensus price target of $140.89 implying 14% upside.

AEP's outlook is supported by contracted load growth and infrastructure investments, but risks include execution of its capital plan and interest expense pressures. The stock offers a dividend yield with an upcoming $0.95 payment. Analyst consensus is strongly bullish with 61% buy ratings, though technical indicators suggest near-term caution. Long-term growth targets of 7–9% annually provide a solid foundation for patient investors.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.